Mirum Pharmaceuticals (MIRM) Earnings Date, Estimates & Call Transcripts $44.50 -1.76 (-3.80%) (As of 11/15/2024 ET) Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Mirum Pharmaceuticals Latest Earnings SummaryUpcoming Q4 Earnings DateFeb. 26EstimatedActual EPS (Nov. 12) -$0.30 Beat By $0.15 Consensus EPS (Nov. 12) -$0.45 Mirum Pharmaceuticals released Q3 2024 earnings on November 12, 2024, reporting an EPS of -$0.30, which beat analysts' consensus estimates of -$0.45 by $0.15. Quarterly revenue rose 89.4% year-over-year to $90.38 million, above analyst estimates of $81.99 million. With a trailing EPS of -$2.02, Mirum Pharmaceuticals' earnings are expected to grow next year, from ($1.51) to ($0.87) per share. Conference Call TranscriptConference Call AudioEarnings Press ReleaseEarnings Slide DeckMIRM Upcoming EarningsMirum Pharmaceuticals' next earnings date is estimated for Wednesday, February 26, 2025, based off prior year's reporting schedules. Get Mirum Pharmaceuticals Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Mirum Pharmaceuticals and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataMIRM Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.MIRM Estimated and Actual Revenue by QuarterEstimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Ad Paradigm Press[Urgent] Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again with Tesla… which is up more than 19,500% since 2010. For perspective, that turns $100 invested into almost $20,000! And now, Elon could be set to do it for the third and final time… with what might be his biggest breakthrough yet. And for the first time ever, you have the rare chance to profit BEFORE the upcoming IPO.Click here now for the urgent details on this hidden play. Mirum Pharmaceuticals Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20242-$0.53$0.05-$0.24Q2 20242-$0.48$0.06-$0.21Q3 20242-$0.30$0.16-$0.07Q4 20242-$0.28-$0.27-$0.28FY 20248-$1.59$0.00-$0.80Q1 20251-$0.09-$0.09-$0.09Q2 20251$0.12$0.12$0.12Q3 20251$0.35$0.35$0.35Q4 20251$0.61$0.61$0.61FY 20254$0.99$0.99$0.99 Mirum Pharmaceuticals Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueLinks 2/26/2025(Estimated)------- 11/12/2024Q3 2024-$0.45-$0.30+$0.15-$0.30$81.99M$90.38M 8/7/2024Q2 2024-$0.47-$0.52 -$0.05-$0.52$75.03M$77.90M 5/8/2024Q1 2024-$0.40-$0.54 -$0.14-$0.54$69.71M$69.22M 2/28/2024Q4 2023-$0.34-$0.66 -$0.32-$0.66$66.73M$69.55M 11/2/2023Q3 2023-$0.64-$0.57+$0.07-$0.57$34.31M$47.73M 8/3/2023Q2 2023-$0.81-$0.92 -$0.11$0.10$30.00M$37.50M Get the Latest News and Ratings for MIRM and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Mirum Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. 5/4/2023Q1 2023-$0.96-$0.80+$0.16-$0.80$30.58M$31.60M 3/8/2023Q4 2022-$0.98-$0.99 -$0.01-$0.99$24.99M$27.91M Mirum Pharmaceuticals Earnings - Frequently Asked Questions When is Mirum Pharmaceuticals's earnings date? Mirum Pharmaceuticals has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, February 26th, 2025 based off last year's report dates. Learn more on MIRM's earnings history. What guidance has Mirum Pharmaceuticals issued on next quarter's earnings? Mirum Pharmaceuticals issued an update on its FY 2024 earnings guidance on Tuesday, November, 12th. The company issued revenue guidance of $330.0 million-$335.0 million, compared to the consensus revenue estimate of $316.2 million. Did Mirum Pharmaceuticals beat their earnings estimates last quarter? In the previous quarter, Mirum Pharmaceuticals (NASDAQ:MIRM) reported ($0.30) earnings per share (EPS) to beat the analysts' consensus estimate of ($0.45) by $0.15. Learn more on analysts' earnings estimate vs. MIRM's actual earnings. How can I listen to Mirum Pharmaceuticals's earnings conference call? The conference call for Mirum Pharmaceuticals's latest earnings report can be listened to online. Listen to Conference Call How can I read Mirum Pharmaceuticals's conference call transcript? The conference call transcript for Mirum Pharmaceuticals's latest earnings report can be read online. Read Transcript How much revenue does Mirum Pharmaceuticals generate each year? Mirum Pharmaceuticals (NASDAQ:MIRM) has a recorded annual revenue of $186.37 million. How much profit does Mirum Pharmaceuticals generate each year? Mirum Pharmaceuticals (NASDAQ:MIRM) has a recorded net income of -$163.41 million. MIRM has generated -$2.02 earnings per share over the last four quarters. What is Mirum Pharmaceuticals's EPS forecast for next year? Mirum Pharmaceuticals's earnings are expected to grow from ($1.51) per share to ($0.87) per share in the next year. ` More Earnings Resources from MarketBeat Related Companies Avid Bioservices Earnings DURECT Earnings Viking Therapeutics Earnings Legend Biotech Earnings Ascendis Pharma A/S Earnings Elanco Animal Health Earnings Cytokinetics Earnings Blueprint Medicines Earnings Lantheus Earnings Nuvalent Earnings Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles MercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Roblox Stock Set for More Gains After Strong Earnings ReportAmazon: Why Analysts Think It's a Solid Buy Ahead of EarningsLam Research Proves Analysts Wrong with a Strong Earnings ReportPulteGroup Earnings Signal Potential Entry Points for Investors [Urgent] Starlink Set For The Largest IPO In History? (Ad)He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again with Tesla… which is up more than 19,500% since 2010. For perspective, that turns $100 invested into almost $20,000! And now, Elon could be set to do it for the third and final time… with what might be his biggest breakthrough yet. And for the first time ever, you have the rare chance to profit BEFORE the upcoming IPO.Click here now for the urgent details on this hidden play. This page (NASDAQ:MIRM) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mirum Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Mirum Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
